Basel: Novartis has announced that the US Food and Drug Administration (FDA) has approved Pluvicto (lutetium Lu 177 ...

Kendrick served as the Diagnostic Radiology Clinical Coordinator from 2001-2008 before becoming the program director ...

We recently published a list of Why These 15 Aerospace Stocks Are Surging In 2025. In this article, we are going to take a ...

The FDA approved a radioligand therapy for earlier use prior to chemotherapy in patients with prostate-specific membrane ...

In the study, Pluvicto (lutetium Lu 177 vipivotide tetraxetan) reduced the risk of radiographic progression or death by 59% ...

Based on additional results from the Phase III PSMAfore clinical trial, the therapy is now approved for use prior to ...

The Food and Drug Administration (FDA) has expanded the approval of Pluvicto® (lutetium Lu 177 vipivotide tetraxetan) to include patients with ...

Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot ...

Novartis said the U.S. Food and Drug Administration has approved the use of Pluvicto against a certain type of prostate cancer. The drug maker said Friday that the FDA green-lit the use of Pluvicto to ...

FDA expands Pluvicto indication to adults with PSMA+ metastatic castration-resistant prostate cancer previously treated with ...

Novartis (NVS) announced that the Food and Drug Administration approved Pluvicto for patients with prostate-specific membrane antigen-positive ...

Patients with radiographic axial spondyloarthritis who receive ixekizumab biweekly demonstrate lower sacroiliac joint erosion and increased the backfill of new tissue through 52 weeks, according to ...